Friday, 19 Jul 2019

You are here

Deprescribing to Battle Polypharmacy

The Gerontological Society of America has published a report calling for deprescribing as a means of managing polypharmacy in the elderly.

Deprescribing is defined as the “the systematic process of identifying and discontinuing drugs in instances in which existing or potential harms outweigh existing or potential benefits within the context of an individual patient’s care goals, current level of functioning, life expectancy, values, and preferences”. 

Several key factors can contribute to polypharmacy in older adults:

  • An increasing complexity of health care delivery, irrespective of the national setting, leading to problems of coordination between caregivers, physicians, and patients;
  • The rise of co-morbidities and chronic long-term illnesses as the population ages;
  • The huge numbers of available pharmaceuticals and their widespread use;
  • The construction of guidelines based on single diseases, randomized control trials of low external validity, and drugs untested in the older population;
  • Marginalization and disempowerment of older patients, with the absence of shared decision-making; and
  • A culture in Western societies that is expectant of medical intervention at all levels.

This address in the new Public Policy & Aging Report addresses ethical and policy issues related to deprescribing and explore the application of this approach in practice, including how to address barriers to deprescribing.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rituximab Superior to Cyclosporine for Membranous Nephropathy

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

FDA Public Review of CBD Oil

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

In his opening remarks, the FDA acting Commissioner Dr. Ned Sharpless said, "critical questions remain about the safety" of CBD products, especially since the growth of the CBD market has exploded in the past year.

Steroids, Not Biologics, Drive Arthroplasty Infections in RA

Medicare and Truven MarketScan administrative data study (2006 through 2015) of rheumatoid arthritis (RA) undergoing arthroplasty found that while that the risks of perioperative infection was similar across biologics, the infection risk with glucocorticoid use, especially at > 10 mg/d, was significantly greater.